Literature DB >> 9521482

Comparison of human alpha1-adrenoceptor subtype coupling to protein kinase C activation and related signalling pathways.

K Taguchi1, M Yang, M Goepel, M C Michel.   

Abstract

The coupling of human alpha1-adrenoceptor subtypes to protein kinase C (PKC) and PKC-related signalling events were investigated in rat-1 fibroblasts stably expressing alpha1A-, alpha1B- or alpha1D-adrenoceptors at densities of 1328+/-200, 5030+/-703 and 150+/-14 fmol/mg protein respectively. In functional assays the alpha1-adrenoceptor agonist phenylephrine significantly stimulated PKC (assessed as increased activity in the membrane fraction) in cells expressing alpha1A- or alpha1B- but not alpha1D-adrenoceptors. In immunoblot assays phorbol ester treatment enhanced membrane-associated immunoreactivity of PKCalpha, PKCdelta and PKCepsilon to a similar extent in all three cell lines. Stimulation of alpha1A- and alpha1B-adrenoceptors also increased immunoreactivity of PKCalpha, PKCdelta and PKCepsilon in the membrane fraction, while alpha1D-adrenoceptor stimulation yielded only very small and inconsistent alterations. Immunoreactivity of PKCzeta was not consistently affected by phorbol ester or phenylephrine in any of the cell lines. Stimulation of all three alpha1-adrenoceptors time- and concentration-dependently increased inositol phosphate formation. Maximum activation occurred with the order alpha1A approximately = alpha1B > alpha1D. Phenylephrine also concentration dependently elevated free intracellular [Ca2+] in all three cell lines with the order of efficacy alpha1A > alpha1B > alpha1D. In the presence of ethanol, phenylephrine stimulated phosphatidylethanol formation in alpha1A- and alpha1B-adrenoceptor-expressing cells time and concentration dependently but only weakly and inconsistently in alpha1D-adrenoceptor-expressing cells. The efficacy of phenylephrine (100 microM) relative to that of noradrenaline (100 microM) for stimulation of phosphatidylethanol formation was similar (> or = 75%) for all three subtypes. The alkylating agent phenoxybenzamine concentration dependently reduced alpha1A-adrenoceptor density and phenylephrine-stimulated Ca2+ elevations to levels seen with alpha1D-adrenoceptors but reductions of phenylephrine-stimulated phosphatidylethanol formation were weaker. We conclude that human alpha1A- and alpha1B-adrenoceptors expressed in rat-1 cells couple to activation of PKCalpha, PKCdelta and PKCepsilon but not PKCzeta; this may involve stimulation of phospholipases C and D and intracellular Ca2+ elevations. Activation of these pathways by alpha1D-adrenoceptors appears to be much weaker and was not detected consistently; this was not fully explained by weak partial agonism of phenylephrine at this subtype or by lower receptor densities. Overall the alpha1A-adrenoceptor may have the highest efficiency of stimulus-response coupling among human alpha1-adrenoceptor subtypes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9521482     DOI: 10.1007/pl00005143

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  15 in total

1.  Sympathetic neural inhibition of conducted vasodilatation along hamster feed arteries: complementary effects of alpha1- and alpha2-adrenoreceptor activation.

Authors:  Sara J Haug; Steven S Segal
Journal:  J Physiol       Date:  2004-12-02       Impact factor: 5.182

2.  Noradrenergic α1-Adrenoceptor Actions in the Primate Dorsolateral Prefrontal Cortex.

Authors:  Dibyadeep Datta; Sheng-Tao Yang; Veronica C Galvin; John Solder; Fei Luo; Yury M Morozov; Jon Arellano; Alvaro Duque; Pasko Rakic; Amy F T Arnsten; Min Wang
Journal:  J Neurosci       Date:  2019-02-12       Impact factor: 6.167

3.  α1 -Adrenoceptor activation of PKC-ε causes heterologous desensitization of thromboxane receptors in the aorta of spontaneously hypertensive rats.

Authors:  Yingzi Zhao; Paul M Vanhoutte; Susan W S Leung
Journal:  Br J Pharmacol       Date:  2015-05-15       Impact factor: 8.739

4.  5-HT1A receptor pharmacophores to screen for off-target activity of α1-adrenoceptor antagonists.

Authors:  Tony Ngo; Timothy J Nicholas; Junli Chen; Angela M Finch; Renate Griffith
Journal:  J Comput Aided Mol Des       Date:  2013-04-27       Impact factor: 3.686

5.  In vivo evidence for a role of protein kinase C in peripheral nociceptive processing.

Authors:  Adriano L S Souza; Fabrício A Moreira; Karine R Almeida; Caryne M Bertollo; Karina A Costa; Márcio M Coelho
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

6.  Agonist-specific coupling of a cloned human alpha1A-adrenoceptor to different second messenger pathways.

Authors:  Joanna Richardson; Heather Chatwin; Akira Hirasawa; Gozoh Tsujimoto; Peter D Evans
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-03-20       Impact factor: 3.000

7.  Functional characterization of alpha 1-adrenoceptor subtypes in vascular tissues using different experimental approaches: a comparative study.

Authors:  Regina Gisbert; Yolanda Madrero; Valentina Sabino; M Antonia Noguera; M Dolores Ivorra; Pilar D'Ocon
Journal:  Br J Pharmacol       Date:  2003-01       Impact factor: 8.739

8.  Extracts from Rhois aromatica and Solidaginis virgaurea inhibit rat and human bladder contraction.

Authors:  Verena E Borchert; Peter Czyborra; Charlotte Fetscher; Mark Goepel; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-02-13       Impact factor: 3.000

9.  Comparison of signalling mechanisms involved in rat mesenteric microvessel contraction by noradrenaline and sphingosylphosphorylcholine.

Authors:  Christoph Altmann; Veronika Steenpass; Peter Czyborra; Peter Hein; Martin C Michel
Journal:  Br J Pharmacol       Date:  2003-01       Impact factor: 8.739

10.  Caveolae contribute to the apoptosis resistance induced by the alpha(1A)-adrenoceptor in androgen-independent prostate cancer cells.

Authors:  Maria Katsogiannou; Charbel El Boustany; Florian Gackiere; Philippe Delcourt; Anne Athias; Pascal Mariot; Etienne Dewailly; Nathalie Jouy; Christophe Lamaze; Gabriel Bidaux; Brigitte Mauroy; Natalia Prevarskaya; Christian Slomianny
Journal:  PLoS One       Date:  2009-09-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.